Immunome Reports First Quarter 2026 Financial Results and Provides Business Update Life Science Investing
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity Life Science Investing
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Life Science Investing
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association 2026 Congress Life Science Investing
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 Life Science Investing
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates Life Science Investing
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights Life Science Investing
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
